Rifaximin
- Generic Name
- Rifaximin
- Brand Names
- Xifaxan, Zaxine
- Drug Type
- Small Molecule
- Chemical Formula
- C43H51N3O11
- CAS Number
- 80621-81-4
- Unique Ingredient Identifier
- L36O5T016N
- Background
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalop...
- Indication
Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in ...
- Associated Conditions
- Bacterial Infections, Clostridium difficile infection recurrence, Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), Traveler's Diarrhea
- Associated Therapies
- -
Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Ospedali Riuniti di Foggia
- Target Recruit Count
- 322
- Registration Number
- NCT04159870
- Locations
- 🇮🇹
Ospedali Riuniti Foggia, Foggia, Italy
Autologous Transplant Targeted Against Crohn's
- Conditions
- Interventions
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT04154735
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Transcranial Doppler Ultrasound and Minimal Hepatic Encephalopathy
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2019-09-04
- Target Recruit Count
- 100
- Registration Number
- NCT04077125
- Locations
- 🇮🇹
Fondazione Policlinico Agostino Gemelli IRCCS, Roma, Italy
Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D
- Conditions
- Interventions
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2020-07-28
- Target Recruit Count
- 240
- Registration Number
- NCT04074421
- Locations
- 🇨🇳
The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Rifaximin and Misoprostol Combination Therapy for Healing of Small Bowel Ulcers in Aspirin Users
- First Posted Date
- 2019-05-24
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 78
- Registration Number
- NCT03962283
- Locations
- 🇭🇰
Prince of Wales Hospital, Hong Kong, Hong Kong
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
Rifaximin in Patients With Monoclonal Gammopathy
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Emory University
- Target Recruit Count
- 48
- Registration Number
- NCT03820817
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT03818672
- Locations
- 🇺🇸
Valeant Site 01, San Antonio, Texas, United States
Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Judit Pich
- Target Recruit Count
- 254
- Registration Number
- NCT03780673
- Locations
- 🇫🇷
Beajuon Hospital, Clichy, Paris, France
🇳🇱Academic Medical Centre, Amsterdam, Netherlands
🇪🇸Hospital Universitari Vall d'Hebrón, Barcelona, Spain
Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea
- Conditions
- Interventions
- First Posted Date
- 2018-11-02
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 110
- Registration Number
- NCT03729271
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Rifaximin to Modify the Disease Course in Sickle Cell Disease
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 20
- Registration Number
- NCT03719729
- Locations
- 🇺🇸
Westchester Medical Cancer Cancer Institute, Valhalla, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.